



# Características clínicas y neuropsicológicas en niños con trastorno del espectro autista atendidos en el Centro Internacional de Restauración Neurológica [

2023

text (article)

Analítica

**Introduction:** Research on the clinical and neuropsychological characteristics of children with autism spectrum disorder report a heterogeneous and atypical profile. Treatment for these children is diverse and pharmacotherapy is a key element for symptom control.**Objective:** To describe the clinical and neuropsychological characteristics in children with autism spectrum disorder.**Material and Methods:** Observational, descriptive study of 20 patients between 2-6 years old with primary autism spectrum disorder, evaluated in the Neuropsychology Service of the International Center for Neurological Restoration, in the period January-December 2022. Demographic, clinical and neuropsychological variables were analyzed using the Autism Rating Scale (CARS) and the Brunet-Lézine psychomotor test. Descriptive statistics was used: for quantitative variables (mean, standard deviation) and for qualitative variables (absolute frequencies and percentage).**Results:** Moderate severity predominated (85%), moderate to severe impairment of the developmental coefficient (60%), severe language impairment (60%), sleep disorder (25%) and 80% responded to carbamazepine.**Conclusions:** Neuropsychological alterations and social limitations of moderate and severe intensity were confirmed in children with autism spectrum disorder, contributing to the evidence already reported in other studies, although it must be taken into consideration that the research was based on a small case series and was carried out in a tertiary health institution. It is recommended to develop studies aimed at validating the efficacy of carbamazepine

**Introduction:** Research on the clinical and neuropsychological characteristics of children with autism spectrum disorder report a heterogeneous and atypical profile. Treatment for these children is diverse and pharmacotherapy is a key element for symptom control.**Objective:** To describe the clinical and neuropsychological characteristics in children with autism spectrum disorder.**Material and Methods:** Observational, descriptive study of 20 patients between 2-6 years old with primary autism spectrum disorder, evaluated in the Neuropsychology Service of the International Center for Neurological Restoration, in the period January-December 2022. Demographic, clinical and neuropsychological variables were analyzed using the Autism Rating Scale (CARS) and the Brunet-Lézine psychomotor test. Descriptive statistics was used: for quantitative variables (mean, standard deviation) and for qualitative variables (absolute frequencies and percentage).**Results:** Moderate severity predominated (85%), moderate to severe impairment of the

developmental coefficient (60%), severe language impairment (60%), sleep disorder (25%) and 80% responded to carbamazepine. Conclusions: Neuropsychological alterations and social limitations of moderate and severe intensity were confirmed in children with autism spectrum disorder, contributing to the evidence already reported in other studies, although it must be taken into consideration that the research was based on a small case series and was carried out in a tertiary health institution. It is recommended to develop studies aimed at validating the efficacy of carbamazepine

<https://rebiunoda.pro.baratznet.cloud:28443/OpacDiscovery/public/catalog/detail/b2FpOmNlbGVicmF0aW9uOmVzLmJhcmF0ei5yZW4vMzYwNzYzOTA>

---

**Título:** Características clínicas y neuropsicológicas en niños con trastorno del espectro autista atendidos en el Centro Internacional de Restauración Neurológica [electronic resource].]

**Editorial:** 2023

**Tipo Audiovisual:** Autism spectrum disorder children neurodevelopment neuropsychology risperidone carbamazepine Trastorno del Espectro Autista Niños Neurodesarrollo Neuropsicología Risperidona Carbamazepina

**Documento fuente:** Revista Habanera de Ciencias Médicas, ISSN 1729-519X, Vol. 22, N°. 6, 2023

**Nota general:** application/pdf

**Restricciones de acceso:** Open access content. Open access content star

**Condiciones de uso y reproducción:** LICENCIA DE USO: Los documentos a texto completo incluidos en Dialnet son de acceso libre y propiedad de sus autores y/o editores. Por tanto, cualquier acto de reproducción, distribución, comunicación pública y/o transformación total o parcial requiere el consentimiento expreso y escrito de aquéllos. Cualquier enlace al texto completo de estos documentos deberá hacerse a través de la URL oficial de éstos en Dialnet. Más información: <https://dialnet.unirioja.es/info/derechosOAI> | INTELLECTUAL PROPERTY RIGHTS STATEMENT: Full text documents hosted by Dialnet are protected by copyright and/or related rights. This digital object is accessible without charge, but its use is subject to the licensing conditions set by its authors or editors. Unless expressly stated otherwise in the licensing conditions, you are free to linking, browsing, printing and making a copy for your own personal purposes. All other acts of reproduction and communication to the public are subject to the licensing conditions expressed by editors and authors and require consent from them. Any link to this document should be made using its official URL in Dialnet. More info: <https://dialnet.unirioja.es/info/derechosOAI>

**Lengua:** Spanish

**Enlace a fuente de información:** Revista Habanera de Ciencias Médicas, ISSN 1729-519X, Vol. 22, N°. 6, 2023

---

## Baratz Innovación Documental

- Gran Vía, 59 28013 Madrid
- (+34) 91 456 03 60
- [informa@baratz.es](mailto:informa@baratz.es)